Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses findings from a multicenter, retrospective study assessing the impact of hormone receptor status on clinical behavior and outcomes in patients with breast cancer under 40 years of age. Hormone receptor status did not seem to be a positive prognostic factor in patients with BRCA1/2 mutations. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
